GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-146861 | Pharmaceuticals and Medical
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Gastrointestinal stromal tumor (GIST) drugs Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET
7.1 GLOBAL GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA GASTROINTESTINAL STROMAL TUMOR (GIST) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Immunicum AB
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Arog Pharmaceuticals, Inc
16.3 F Hoffmann-La Roche Ltd
16.4 Array BioPharma Inc
16.5 Deciphera Pharmaceuticals, LLC
16.6 Calithera Biosciences, Inc
16.7 Omeros Corporation
16.8 Natco Pharma Limited
16.9 Chipscreen Biosciences Ltd
16.10 Kolltan Pharmaceuticals, Inc
16.11 Ariad Pharmaceuticals, Inc
16.12 Nerviano Medical Sciences Srl
16.13 Novartis AG
16.14 Astex Pharmaceuticals, Inc
16.15 Jiangsu Hengrui Medicine Co, Ltd
16.16 Blueprint Medicines Corporation
16.17 Horizon Pharma Plc
16.18 Boston Biomedical, Inc
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Major Types CoveredBinimetinib
Other types
Amcasertib
APG-1351
Anagrelide hydrochloride CR
Major Downstream Industry Covered
hospital
clinic
Other applications
Companies
Immunicum AB
Arog Pharmaceuticals, Inc
F Hoffmann-La Roche Ltd
Array BioPharma Inc
Deciphera Pharmaceuticals, LLC
Calithera Biosciences, Inc
Omeros Corporation
Natco Pharma Limited
Chipscreen Biosciences Ltd
Kolltan Pharmaceuticals, Inc
Ariad Pharmaceuticals, Inc
Nerviano Medical Sciences Srl
Novartis AG
Astex Pharmaceuticals, Inc
Jiangsu Hengrui Medicine Co, Ltd
Blueprint Medicines Corporation
Horizon Pharma Plc
Boston Biomedical, Inc
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.